GH

Guardant Health Inc

Sep 18 • 04:00PM ET

58.80

+1.61 2.82 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ILMN QGEN EXAS FLGT BIO SRPT MYGN NTRA CDNA TXG

| Held by: VTI VB IWM VBK VXF IWO ARKG VTWO CGGR SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.35	Insider Own	4.44%	Shs Outstand	124.48M	Perf Week	3.53%
Market Cap	7.33B	Forward P/E	-	EPS next Y	-2.70	Insider Trans	-10.77%	Shs Float	119.17M	Perf Month	0.39%
Enterprise Value	8.04B	PEG	-	EPS next Q	-0.79	Inst Own	100.20%	Short Float	6.73%	Perf Quarter	16.27%
Income	-413.82M	P/S	8.85	EPS this Y	12.23%	Inst Trans	3.07%	Short Ratio	3.21	Perf Half Y	27.16%
Sales	828.85M	P/B	-	EPS next Y	13.47%	ROA	-28.14%	Short Interest	8.02M	Perf YTD	92.47%
Book/sh	-2.45	P/C	11.66	EPS next 5Y	17.51%	ROE	-4584.47%	52W High	68.00 -13.53%	Perf Year	131.68%
Cash/sh	5.04	P/FCF	-	EPS past 3/5Y	3.89% -33.61%	ROIC	-41.28%	52W Low	20.14 191.96%	Perf 3Y	-3.61%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	25.52% 28.08%	Gross Margin	62.84%	Volatility	4.23% 3.94%	Perf 5Y	-38.30%
Dividend TTM	-	EV/Sales	9.70	EPS Y/Y TTM	18.25%	Oper. Margin	-55.59%	ATR (14)	2.60	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.35	Sales Y/Y TTM	28.74%	Profit Margin	-49.93%	RSI (14)	53.29	Recom	1.54
Dividend Gr. 3/5Y	- -	Current Ratio	3.71	EPS Q/Q	3.96%	SMA20	-2.85%	Beta	1.54	Target Price	60.67
Payout	-	Debt/Eq	-	Sales Q/Q	30.95%	SMA50	8.98%	Rel Volume	0.72	Prev Close	57.19
Employees	2021	LT Debt/Eq	-	Earnings	Jul 30 AMC	SMA200	29.15%	Avg Volume	2.50M	Price	58.80
IPO	Oct 04, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.04% 9.75%	Trades		Volume	1,793,992	Change	2.82%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-25	Initiated	Mizuho	Outperform	$55
Jan-23-25	Initiated	Barclays	Overweight	$60
Jun-28-24	Upgrade	Guggenheim	Neutral → Buy	$36
Jun-03-24	Resumed	Jefferies	Buy	$32
Apr-24-24	Resumed	Craig Hallum	Buy	$28
Dec-14-23	Initiated	Guggenheim	Neutral
Dec-13-23	Initiated	Wolfe Research	Peer Perform
Nov-13-23	Upgrade	Raymond James	Mkt Perform → Outperform	$27
Sep-28-23	Initiated	Bernstein	Outperform	$34
Sep-27-23	Upgrade	Piper Sandler	Neutral → Overweight	$40
Jul-05-23	Resumed	JP Morgan	Overweight	$65
May-26-23	Upgrade	Citigroup	Neutral → Buy	$28 → $40
May-05-23	Initiated	UBS	Buy	$40
Mar-09-23	Downgrade	Citigroup	Buy → Neutral	$60 → $33
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$36
Nov-01-22	Downgrade	Piper Sandler	Overweight → Neutral	$65 → $50
Oct-19-22	Initiated	Craig Hallum	Buy	$88
Oct-06-22	Initiated	Stephens	Overweight	$99
Aug-25-22	Initiated	Credit Suisse	Outperform	$80
Jun-03-22	Initiated	Piper Sandler	Overweight	$65

Show Previous Ratings

Sep-17-25 11:33PM	Q2 Earnings Recap: Guardant Health (NASDAQ:GH) Tops Testing & Diagnostics Services Stocks (StockStory)
Sep-15-25 04:07PM	Alex M. Azar II Joins Guardant Health Board of Directors (Business Wire)
Sep-11-25 05:33PM	More Blood Tests for Cancer Hit the Market (Barrons.com)
08:05AM	Guardant Health Expands Access to Shield CRC Blood Test to Senior Living Communities with LabFlorida Partnership (Business Wire)
Sep-10-25 07:03PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
08:05AM	Loading…
Sep-08-25 08:05AM	Guardant Health Announces Partnership with PathGroup Bringing Shield Blood Test to 250+ Hospitals and Health Systems in 25 States (Business Wire)
Sep-05-25 05:28AM	Guardant Health reports positive clinical readout update for Shield algorithm (Medical Device Network)
Sep-04-25 12:30PM	What's Fueling Tempus AI's Q2 Net Loss Improvement Momentum? (Zacks) -5.69%
12:16PM	Why Guardant Health (GH) Shares Are Plunging Today (StockStory)
12:16PM	Why IBD 50's Guardant Health Just Tumbled, Breaking A 67% Monthlong Run (Investor's Business Daily)
08:06AM	Guardant Health Announces Clinical Result Update for Shield Blood-Based Colorectal Cancer Screening Test (Business Wire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire)
Aug-28-25 04:05PM	Guardant Health to Host Investor Day on September 24, 2025 (Business Wire)
Aug-26-25 04:05PM	Guardant Health to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference (Business Wire)
Aug-15-25 05:05PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:15AM	Loading…
09:15AM	TMO Receives FDA Approval for Oncomine Dx Target Test (Zacks)
Aug-14-25 06:50PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
Aug-13-25 08:37AM	TEM Once Again Raises Its 2025 Sales Guidance: What's Driving the Move? (Zacks) +6.30%
Aug-12-25 11:56PM	The 5 Most Interesting Analyst Questions From Guardant Health's Q2 Earnings Call (StockStory)
11:49PM	GH Q2 Deep Dive: Strong Volume Growth and Product Expansion Amid Profitability Challenges (StockStory)
Aug-11-25 09:06AM	Multi Cancer Early Detection Market Forecast Report 2025-2033: A $4.3 Billion Market by 2033, as Market Set to Quadruple from $1 Billion Valuation in 2024 (GlobeNewswire)
Aug-04-25 08:06AM	American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity (Business Wire) +6.69%
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-31-25 04:05PM	Guardant Health to Participate in the Canaccord Genuity 45th Annual Growth Conference (Business Wire) -9.32%
11:26AM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
03:33AM	Guardant Health Inc (GH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Raised ... (GuruFocus.com)
Jul-30-25 07:00PM	Guardant Health (GH) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:36PM	Guardant Health (NASDAQ:GH) Beats Expectations in Strong Q2, Guides for Strong Full-Year Sales (StockStory)
06:00PM	Guardant Health (GH) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:57PM	Guardant Health: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Guardant Health Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (Business Wire)
08:09AM	Guardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+ (Business Wire)
Jul-29-25 08:43AM	Tempus AI Taps Growing ICI Market With New xM Assay (Zacks)
08:07AM	New RADIOHEAD Study Validates Use of Guardant Reveal Tissue-Free Monitoring for Earlier Detection of Immunotherapy Response in Advanced Cancer (Business Wire)
Jul-28-25 11:08PM	Guardant Health (GH) Q2 Earnings: What To Expect (StockStory)
Jul-24-25 06:26AM	Cathie Wood's Bold AI and Genomics Playbooks Revealed (GuruFocus.com)
06:22AM	Cathie Wood Pours Millions into Nvidia and Biotech, Dumps Rocket Lab (GuruFocus.com)
Jul-23-25 12:05AM	3 Reasons to Avoid GH and 1 Stock to Buy Instead (StockStory)
Jul-15-25 11:01AM	First Patient Enrolled in National Cancer Institute's Vanguard Study Evaluating Guardant Health's Shield Multi-Cancer Detection Test (Business Wire)
Jul-14-25 08:00AM	Guardant Health to Report Second Quarter 2025 Financial Results on July 30, 2025 (Business Wire)
Jul-11-25 03:31PM	Guardant Health, Gilead Sciences, Inspire Medical Systems, Enovis, and AMN Healthcare Services Stocks Trade Down, What You Need To Know (StockStory)
Jul-04-25 08:43AM	Tempus AI Revenues & Profit Rise: What to Expect Ahead of Q2 Release (Zacks)
Jun-30-25 07:26AM	The 5 Most Interesting Analyst Questions From Guardant Health's Q1 Earnings Call (StockStory)
Jun-25-25 08:51AM	The Top 5 Analyst Questions From Guardant Health's Q1 Earnings Call (StockStory)
Jun-23-25 03:00PM	TEM vs. GH: Which AI in Precision Oncology Stock Has More Upside Now? (Zacks)
12:07PM	Medical Services Name Flirts With A Buy Point (Investor's Business Daily)
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks)
Jun-19-25 05:54PM	How Will Dow Jones Futures Open As Trump Says 'Two Weeks' For Iran Decision? (Investor's Business Daily)
03:35PM	Will Dow Jones Futures Rebound As Trump Says 'Two Weeks' For Iran Decision? (Investor's Business Daily)
Jun-13-25 12:35AM	3 of Wall Street's Favorite Stocks Facing Headwinds (StockStory)
Jun-10-25 07:05AM	Guardant Health Wins Fast Company's 2025 World Changing Ideas Award for Shield Blood Test for Colorectal Cancer Screening (Business Wire)
Jun-09-25 08:05AM	New Study Published in ESMO Open Highlights Guardant Reveal's Performance in Detecting Minimal Residual Disease in Patients with Early-Stage Breast Cancer (Business Wire)
Jun-06-25 09:09AM	Tempus AI Eyes Positive Adjusted EBITDA in 2025: Is It Taking Shape? (Zacks)
Jun-04-25 09:45AM	Guardant Healths MCD test earns FDA breakthrough designation (Medical Device Network)
Jun-03-25 05:48PM	Why Guardant Health Stock Surged Nearly 9% Higher Today (Motley Fool) +8.76%
08:05AM	FDA Grants Breakthrough Device Designation to Guardant Health's Shield Multi-Cancer Detection (MCD) Test (Business Wire)
Jun-02-25 08:05AM	National Comprehensive Cancer Network (NCCN) Updates Colorectal Cancer Screening Guidelines to Include Shield Blood-Based Screening (Business Wire)
07:00AM	SERENA-6 Phase III Trial Demonstrates Clinical Value of Guardant360 CDx Test to Detect Emergence of Endocrine Resistance and Inform a Switch in Therapy Before Radiological Disease Progression in Advanced Breast Cancer (Business Wire)
May-31-25 08:05AM	In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Timely Treatment Decisions (Business Wire)
May-28-25 11:39PM	Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers (Insider Monkey)
May-27-25 11:38PM	Firing on All Cylinders: Guardant Health (NASDAQ:GH) Q1 Earnings Lead the Way (StockStory)
05:30PM	Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test (Business Wire)
May-23-25 10:00AM	New Tests Promise to Reveal the Secrets in Your Blood (The Wall Street Journal)
May-22-25 05:05PM	Guardant Health and Collaborators to Present Over 19 Studies Demonstrating Role of Liquid Biopsy in Advancing Precision Oncology at 2025 ASCO Annual Meeting (Business Wire)
May-21-25 04:58PM	Guardant Health, Evolent Health, Charles River Laboratories, Avantor, and Lumen Stocks Trade Down, What You Need To Know (StockStory) -7.21%
04:33PM	Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio (Insider Monkey)
08:05AM	Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors (Business Wire)
May-20-25 08:05AM	Guardant Health Introduces Hereditary Cancer Testing to Identify Inherited Predispositions to Certain Types of Cancer (Business Wire)
May-16-25 07:30PM	Guardant Health: A Promising Player in the Liquid Biopsy Market (Motley Fool)
May-14-25 06:20AM	Is First Trust Mid Cap Growth AlphaDEX ETF (FNY) a Strong ETF Right Now? (Zacks)
May-08-25 04:05PM	Guardant Health to Participate in Upcoming Investor Conferences (Business Wire)
09:20AM	TIME Names Guardant Health Co-CEOs to 2025 TIME100 Health List of the 100 Most Influential People in Global Health This Year (Business Wire)
May-07-25 05:05PM	Guardant Health Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.22%
May-01-25 04:33PM	Guardant Health: Tailwinds Are Beginning To Impact The Financials (Seeking Alpha)
12:52PM	Analyst Report: Guardant Health, Inc. (Morningstar Research)
12:04PM	Q1 2025 Guardant Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:18AM	Guardant Health Inc (GH) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Apr-30-25 10:25PM	Guardant Health, Inc. (GH) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:50PM	Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:50PM	Guardant Health's (NASDAQ:GH) Q1: Strong Sales, Stock Soars (StockStory)
04:47PM	Guardant Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Guardant Health Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance (Business Wire)
Apr-29-25 04:20PM	Guardant Health Presents Data Demonstrating Strong Performance of Shield Multi-Cancer Detection Test Across 10 Tumor Types (Business Wire)
08:45AM	Repligen (RGEN) Tops Q1 Earnings and Revenue Estimates (Zacks)
03:06AM	Guardant Health (GH) Q1 Earnings Report Preview: What To Look For (StockStory)
Apr-28-25 09:12AM	CORRECTING and REPLACING Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer (Business Wire)
08:05AM	Guardant Health Launches Guardant360 Tissue, First Tissue Molecular Profiling Test with Comprehensive Multiomic Analysis to Provide a More Complete View of Cancer (Business Wire)
Apr-24-25 03:36PM	Guardant Health, Pfizer Collaborate To Develop New Cancer Therapies Using Liquid Biopsy Platform (Benzinga)
10:01AM	Amgen (AMGN) Earnings Expected to Grow: Should You Buy? (Zacks)
09:45AM	Aristotle Focus Growth Q1 2025 Commentary (Seeking Alpha)
08:05AM	Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform (Business Wire)
Apr-23-25 06:06PM	BBSC: Lagging Several Small-Cap Core ETFs (Seeking Alpha)
10:01AM	Earnings Preview: Guardant Health (GH) Q1 Earnings Expected to Decline (Zacks)
Apr-22-25 10:48AM	Guardant Health (GH) Rose Following Several Positive News Reports (Insider Monkey)
08:05AM	Guardant Health to Present Data Highlighting Advances in Multi-Cancer Detection and Liquid and Tissue Molecular Profiling at AACR (Business Wire)
Apr-21-25 05:01AM	3 Reasons to Sell GH and 1 Stock to Buy Instead (StockStory) -5.25%
Apr-17-25 04:15PM	The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It. (Investor's Business Daily)
Apr-15-25 10:05AM	Guardant Health price target raised to $60 from $56 at BofA (TipRanks)
Apr-14-25 10:51PM	Aristotle Atlantic's Core Equity Q1 2025 Commentary (Seeking Alpha)
02:09PM	Aristotle Large Cap Growth Q1 2025 Commentary (Seeking Alpha)

Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in December 2011 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hidalgo Medina Manuel	Director	Sep 17 '25	Option Exercise	0.00	232	0	1,083	Sep 18 04:33 PM
Tariq Musa	Director	Sep 15 '25	Option Exercise	0.00	249	0	7,707	Sep 17 05:17 PM
Tariq Musa	Director	Sep 17 '25	Sale	55.63	116	6,453	7,591	Sep 17 05:17 PM
POTTER MYRTLE S	Director	Sep 15 '25	Option Exercise	0.00	68	0	18,307	Sep 17 05:17 PM
POTTER MYRTLE S	Director	Sep 17 '25	Sale	55.63	26	1,446	18,281	Sep 17 05:17 PM
Saia John G.	Chief Legal Officer	Sep 15 '25	Option Exercise	0.00	1,019	0	45,967	Sep 17 05:16 PM
Kalia Kumud	Chief Information Officer	Sep 15 '25	Option Exercise	0.00	638	0	19,488	Sep 17 05:15 PM
Freeman Chris	Chief Commercial Officer	Sep 15 '25	Option Exercise	0.00	1,402	0	50,223	Sep 17 05:15 PM
EAGLE CRAIG	Chief Medical Officer	Sep 15 '25	Option Exercise	0.00	1,402	0	38,193	Sep 17 05:14 PM
Bell Michael Brian	Chief Financial Officer	Sep 15 '25	Option Exercise	0.00	3,272	0	46,300	Sep 17 05:13 PM
POTTER MYRTLE S	Director	Sep 17 '25	Proposed Sale	55.62	26	1,446		Sep 17 04:17 PM
Tariq Musa	Director	Sep 17 '25	Proposed Sale	55.63	116	6,453		Sep 17 04:16 PM
Hidalgo Medina Manuel	Director	Sep 12 '25	Sale	54.16	2,165	117,251	851	Sep 15 05:09 PM
Hidalgo Medina Manuel	Director	Sep 12 '25	Proposed Sale	54.16	2,165	117,251		Sep 12 04:25 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Sep 09 '25	Sale	59.45	300,000	17,835,995	2,123,499	Sep 11 07:14 PM
Eltoukhy Helmy	Officer	Sep 09 '25	Proposed Sale	59.45	300,000	17,835,990		Sep 09 05:32 PM
Joyce Meghan V.	Director	Sep 02 '25	Sale	65.84	100	6,584	11,183	Sep 03 06:50 PM
Saia John G.	Chief Legal Officer	Sep 01 '25	Option Exercise	0.00	264	0	45,087	Sep 03 06:47 PM
Kalia Kumud	Chief Information Officer	Sep 01 '25	Option Exercise	0.00	711	0	19,211	Sep 03 06:46 PM
Chudova Darya	Chief Technology Officer	Sep 01 '25	Option Exercise	0.00	316	0	81,610	Sep 03 06:44 PM
Krognes Steve E.	Director	Aug 31 '25	Option Exercise	0.00	155	0	18,128	Sep 03 06:43 PM
Joyce Meghan V.	Director	Sep 02 '25	Proposed Sale	65.84	100	6,584		Sep 02 04:04 PM
Kalia Kumud	Chief Information Officer	Aug 21 '25	Sale	61.76	2,000	123,510	18,500	Aug 22 04:58 PM
Kalia Kumud	Officer	Aug 21 '25	Proposed Sale	61.76	2,000	123,510		Aug 21 04:19 PM
Tariq Musa	Director	Aug 19 '25	Sale	59.02	116	6,846	7,458	Aug 20 07:53 PM
POTTER MYRTLE S	Director	Aug 19 '25	Sale	59.02	26	1,535	18,239	Aug 20 07:51 PM
Tariq Musa	Director	Aug 19 '25	Proposed Sale	59.02	116	6,846		Aug 19 04:36 PM
POTTER MYRTLE S	Director	Aug 19 '25	Proposed Sale	59.02	26	1,535		Aug 19 04:35 PM
Hidalgo Medina Manuel	Director	Aug 17 '25	Option Exercise	0.00	232	0	3,016	Aug 18 05:44 PM
Tariq Musa	Director	Aug 15 '25	Option Exercise	0.00	250	0	7,574	Aug 18 05:43 PM
POTTER MYRTLE S	Director	Aug 15 '25	Option Exercise	0.00	69	0	18,265	Aug 18 05:41 PM
Joyce Meghan V.	Director	Aug 04 '25	Option Exercise	0.00	67	0	11,283	Aug 06 04:57 PM
Krognes Steve E.	Director	Jul 31 '25	Option Exercise	0.00	154	0	17,973	Aug 04 07:13 PM
Tariq Musa	Director	Jul 17 '25	Sale	48.20	116	5,591	7,324	Jul 18 05:25 PM
POTTER MYRTLE S	Director	Jul 17 '25	Sale	48.20	26	1,253	18,196	Jul 18 05:24 PM
Hidalgo Medina Manuel	Director	Jul 17 '25	Option Exercise	0.00	2,784	0	2,784	Jul 18 05:22 PM
Tariq Musa	Director	Jul 17 '25	Proposed Sale	48.20	116	5,591		Jul 17 04:39 PM
POTTER MYRTLE S	Director	Jul 17 '25	Proposed Sale	48.19	26	1,253		Jul 17 04:35 PM
Tariq Musa	Director	Jul 15 '25	Option Exercise	0.00	250	0	7,440	Jul 16 05:11 PM
POTTER MYRTLE S	Director	Jul 15 '25	Option Exercise	0.00	68	0	18,222	Jul 16 05:10 PM
Joyce Meghan V.	Director	Jul 04 '25	Option Exercise	0.00	66	0	11,216	Jul 07 04:44 PM
Saia John G.	Chief Legal Officer	Jul 01 '25	Option Exercise	0.00	2,641	0	46,209	Jul 02 09:26 PM
Kalia Kumud	Chief Information Officer	Jul 01 '25	Option Exercise	0.00	2,691	0	21,865	Jul 02 09:25 PM
Freeman Chris	Chief Commercial Officer	Jul 01 '25	Option Exercise	0.00	3,596	0	50,353	Jul 02 09:24 PM
EAGLE CRAIG	Chief Medical Officer	Jul 01 '25	Option Exercise	0.00	3,381	0	38,505	Jul 02 09:22 PM
Chudova Darya	Chief Technology Officer	Jul 01 '25	Option Exercise	0.00	3,007	0	82,819	Jul 02 09:21 PM
Bell Michael Brian	Chief Financial Officer	Jul 01 '25	Option Exercise	0.00	2,084	0	44,085	Jul 02 09:20 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jun 30 '25	Option Exercise	0.00	4,815	0	2,074,271	Jul 02 09:18 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jul 01 '25	Option Exercise	0.00	23,997	0	1,995,827	Jul 02 09:18 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jul 01 '25	Sale	50.88	100,000	5,087,630	1,971,830	Jul 02 09:18 PM
Krognes Steve E.	Director	Jun 30 '25	Option Exercise	0.00	154	0	17,819	Jul 02 09:17 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Jun 30 '25	Option Exercise	0.00	4,815	0	2,414,105	Jul 02 09:16 PM
Eltoukhy Helmy	Co-Chief Executive Officer	Jul 01 '25	Option Exercise	0.00	23,997	0	2,435,661	Jul 02 09:16 PM
Tariq Musa	Director	Jun 18 '25	Sale	49.47	3,213	158,947	7,190	Jun 20 05:42 PM
POTTER MYRTLE S	Director	Jun 18 '25	Sale	49.47	26	1,286	18,154	Jun 20 05:40 PM
CLARK IAN T	Director	Jun 17 '25	Sale	48.38	6,672	322,819	9,851	Jun 20 05:26 PM
POTTER MYRTLE S	Director	Jun 18 '25	Proposed Sale	49.46	26	1,286		Jun 18 05:00 PM
Tariq Musa	Director	Jun 18 '25	Proposed Sale	49.47	3,213	158,947		Jun 18 04:43 PM
CLARK IAN T	Director	Jun 17 '25	Proposed Sale	48.38	6,672	322,818		Jun 17 04:01 PM
Saia John G.	Chief Legal Officer	Jun 15 '25	Option Exercise	0.00	1,020	0	44,103	Jun 16 08:05 PM
Kalia Kumud	Chief Information Officer	Jun 15 '25	Option Exercise	0.00	637	0	19,402	Jun 16 08:04 PM
Freeman Chris	Chief Commercial Officer	Jun 15 '25	Option Exercise	0.00	6,281	0	49,432	Jun 16 08:03 PM
EAGLE CRAIG	Chief Medical Officer	Jun 15 '25	Option Exercise	0.00	1,402	0	35,835	Jun 16 08:01 PM
Bell Michael Brian	Chief Financial Officer	Jun 15 '25	Option Exercise	0.00	3,272	0	43,660	Jun 16 07:59 PM
POTTER MYRTLE S	Director	Jun 12 '25	Option Exercise	0.00	6,674	0	20,737	Jun 16 07:28 PM
POTTER MYRTLE S	Director	Jun 15 '25	Option Exercise	0.00	69	0	20,806	Jun 16 07:28 PM
POTTER MYRTLE S	Director	Jun 16 '25	Sale	49.70	2,626	130,512	18,180	Jun 16 07:28 PM
Joyce Meghan V.	Director	Jun 12 '25	Option Exercise	0.00	6,674	0	14,487	Jun 16 07:27 PM
Joyce Meghan V.	Director	Jun 13 '25	Sale	47.22	3,337	157,573	11,150	Jun 16 07:27 PM
Tariq Musa	Director	Jun 12 '25	Option Exercise	0.00	6,674	0	10,153	Jun 16 07:25 PM
Tariq Musa	Director	Jun 15 '25	Option Exercise	0.00	250	0	10,403	Jun 16 07:25 PM
Krognes Steve E.	Director	Jun 12 '25	Option Exercise	0.00	6,674	0	17,665	Jun 16 07:24 PM
Gadde Vijaya	Director	Jun 12 '25	Option Exercise	0.00	6,674	0	24,314	Jun 16 07:23 PM
CLARK IAN T	Director	Jun 12 '25	Option Exercise	0.00	8,088	0	16,523	Jun 16 07:21 PM
POTTER MYRTLE S	Director	Jun 16 '25	Proposed Sale	49.70	2,626	130,512		Jun 16 04:20 PM
Joyce Meghan V.	Director	Jun 13 '25	Proposed Sale	47.22	3,337	157,573		Jun 13 04:03 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jun 09 '25	Sale	50.09	77,853	3,899,937	2,069,456	Jun 09 09:45 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jun 06 '25	Sale	50.07	39,751	1,990,420	2,147,309	Jun 09 09:45 PM
Talasaz AmirAli	Co-Chief Executive Officer	Jun 05 '25	Sale	50.00	1,680	84,007	2,187,060	Jun 09 09:45 PM
Joyce Meghan V.	Director	Jun 04 '25	Option Exercise	0.00	67	0	7,813	Jun 05 07:14 PM
Kalia Kumud	Chief Information Officer	Jun 03 '25	Sale	46.39	4,000	185,562	18,765	Jun 05 07:00 PM
Joyce Meghan V.	Director	Jun 02 '25	Sale	41.66	100	4,166	7,746	Jun 03 05:49 PM
Kalia Kumud	Officer	Jun 03 '25	Proposed Sale	46.39	4,000	185,562		Jun 03 04:33 PM
Saia John G.	Chief Legal Officer	Jun 01 '25	Option Exercise	0.00	263	0	43,221	Jun 02 06:05 PM
Kalia Kumud	Chief Information Officer	Jun 01 '25	Option Exercise	0.00	710	0	23,019	Jun 02 06:04 PM
Chudova Darya	Chief Technology Officer	Jun 01 '25	Option Exercise	0.00	316	0	79,973	Jun 02 06:03 PM
Krognes Steve E.	Director	May 31 '25	Option Exercise	0.00	154	0	10,991	Jun 02 06:01 PM
Joyce Meghan V.	Director	Jun 02 '25	Proposed Sale	41.66	100	4,166		Jun 02 04:05 PM
Tariq Musa	Director	May 19 '25	Sale	40.04	116	4,645	3,479	May 20 04:57 PM
Tariq Musa	Director	May 15 '25	Option Exercise	0.00	250	0	3,595	May 19 07:12 PM
POTTER MYRTLE S	Director	May 15 '25	Option Exercise	0.00	68	0	14,063	May 19 07:11 PM
EAGLE CRAIG	Chief Medical Officer	May 15 '25	Option Exercise	0.00	3,718	0	36,318	May 19 07:09 PM
Chudova Darya	Chief Technology Officer	May 15 '25	Option Exercise	0.00	8,705	0	83,210	May 19 07:08 PM
Tariq Musa	Director	May 19 '25	Proposed Sale	40.04	116	4,645		May 19 04:04 PM
Joyce Meghan V.	Director	May 04 '25	Option Exercise	0.00	66	0	7,846	May 05 09:03 PM
Talasaz AmirAli	Co-Chief Executive Officer	May 01 '25	Sale	49.01	106,784	5,233,421	2,202,672	May 05 09:02 PM
Talasaz AmirAli	Co-Chief Executive Officer	May 02 '25	Sale	50.47	13,932	703,151	2,188,740	May 05 09:02 PM
Krognes Steve E.	Director	Apr 30 '25	Option Exercise	0.00	155	0	10,837	May 01 04:56 PM
Talasaz AmirAli	Officer	May 01 '25	Proposed Sale	49.01	340,000	16,663,196		May 01 04:56 PM
Tariq Musa	Director	Apr 17 '25	Sale	44.79	116	5,196	3,345	Apr 18 01:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GH

Guardant Health Inc

Upgrade your FINVIZ experience